


Friday Satellite Symposia



MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies:

Techniques, Utilization, and Best Practices to Optimize Patient Outcomes

IN-PERSON + LIVE STREAMING SATELLITE SYMPOSIUM

DECEMBER 9, 2022

11:00 AM – 2:00 PM CST

PROGRAM CHAIR

C. Ola Landgren, MD, PhD

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoper.

Dear Colleague:

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes**.

This cutting-edge program will provide physicians with the tools to apply minimal/measurable residual disease (MRD) assessment with confidence in their clinical practice. The expert faculty will address the key considerations of MRD testing in a wide range of hematologic malignancies, including acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. Interactive Medical Crossfire® panels will allow discussion on the application of data to clinical practice, and participants will also have the opportunity to ask questions directly to the experts.

In working together with PER®, we strive to make this activity, along with all PER®'s accredited continuing education (CE) activities, both useful and impactful for health care professionals who are involved with the care of patients with hematologic malignancies.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of hematologic malignancies. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

C. Ola Landgren, MD, PhD

Professor of Medicine
Chief, Myeloma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Jim Palatine, RPh, MBA

President
Physicians' Education Resource®, LLC
Cranbury, NJ
jpalatine@mjhlifesciences.com

AGENDA

11:00 AM	Welcome, Introductions, and Presession Survey Overview of MRD in 2022: Clinical Trials Versus Real-World Practice	C. Ola Landgren, MD, PhD
11:25 AM	Current Best Practices in MRD Assessment for Patients With Chronic Lymphocytic Leukemia	Paolo Ghia, MD, PhD
11:50 AM	Medical Crossfire Panel Discussion: Personalizing Treatment Decisions in CLL Using MRD in 2022	Moderator: C. Ola Landgren, MD, PhD
12:00 PM	Current Best Practices in Acute Lymphoblastic Leukemia Management as Informed by MRD Assessment	Aaron C. Logan, MD, PhD
12:25 PM	Medical Crossfire Panel Discussion: Current Best Practices in Guiding Treatment Based on MRD Status	Moderator: C. Ola Landgren, MD, PhD
12:35 PM	Therapeutic Response Assessment in Multiple Myeloma, Including Considerations in the Post-Transplant Setting	C. Ola Landgren, MD, PhD
1:00 PM	Medical Crossfire Panel Discussion: Using MRD to Guide Treatment Decisions in Multiple Myeloma	Moderator: C. Ola Landgren, MD, PhD
1:10 PM	The Future for MRD Assessment in Diffuse Large B-Cell Lymphoma	Reid W. Merryman, MD
1:30 PM	Medical Crossfire Panel Discussion: MRD Monitoring and DLBCL Care	Moderator: C. Ola Landgren, MD, PhD
1:40 PM	Postsession Survey	
1:45 PM	Question-and-Answer Session	
2:00 PM	Adjourn	

Upcoming PER® Conferences

2022

Inaugural International Congress Pediatric Oncology

December 16

2023

The 1st Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™

Honolulu, HI

January 21

20th Annual Winter Lung Conference®

Hollywood, FL

February 3-5

19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Dallas, TX

February 4

27th Annual International Congress on Hematologic Malignancies®

Miami Beach, FL

February 23-26

40th Annual Miami Breast Cancer Conference®

Miami Beach, FL

March 2-5

NYGU™ 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

New York, NY

March 10-11

8th Annual School of Gastrointestinal Oncology®

Orlando, FL

May 6

7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards

May 6

14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

May 13

22nd Annual International Congress on the Future of Breast Cancer® East

New York, NY

July 15-16

24th Annual International Lung Cancer Congress®

Huntington Beach, CA

July 27-29

22nd Annual International Congress on the Future of Breast Cancer® West

San Diego, CA

July 28-29

20th Annual Meeting of the International Society of Gastrointestinal Oncology®

Tempe, AZ

October 13-14

21st Annual School of Breast Oncology®

Atlanta, GA

November 2-4

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®

New York, NY

November 8-10

18th Annual New York Lung Cancers Symposium®

New York, NY

November 11



Virtual Conference



In-Person + Virtual Conference



In-Person Conference

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in MRD monitoring for patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in MRD monitoring for patients with hematologic malignancies are also invited to attend.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Explain best practices in the assessment of MRD across hematologic malignancies, including the techniques and platforms
- Determine guideline recommendations and expert consensus to inform the use of MRD monitoring in hematologic malignancies' settings
- Analyze the role of MRD assessment when planning treatment across the continuum of care for hematologic malignancies
- Formulate plans to integrate emerging data, sampling techniques, MRD assessment, and clinical trial data into the management of patients with hematologic malignancies.

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EST the next business day after the presentation. To access these materials, please visit <https://www.gotoper.com/mrd1222iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit <https://www.gotoper.com/mrd1222iss-eval>.

The online evaluation will be available at the end of the day and the request for credit will be available beginning December 9, 2022 and will remain available until January 23, 2023.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 3.0 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Educational Grant Support

This activity is supported by educational grants from AbbVie, Janssen; administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme.

Thank you for attending **MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes!**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.



Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Other
C. Ola Landgren, MD, PhD	Amgen; Celgene; Janssen; Takeda	Adaptive Biotechnologies; Bristol Meyers Squibb; Celgene; GSK; Janssen; Karyopharm Therapeutics Inc; Merck; Pfizer Inc; Sanofi	IDMC – AstraZeneca; Janssen; Merck; Takeda
Paolo Ghia, MD, PhD	AbbVie; AstraZeneca; Janssen; MSD	AbbVie; AstraZeneca; Bristol Meyers Squibb; Janssen; Loxo Oncology/Lilly; MSD; Roche	
Aaron C. Logan, MD, PhD	Amgen; Astellas Pharma Inc; Autolus Therapeutics; Kadmon; Kite; Pharmacyclics	AbbVie; Bristol Meyers Squibb; Pfizer Inc	
Reid W. Merryman, MD	Merck, Bristol Myers Squibb, Genmab, Genentech/Roche	Genmab, Adaptive Biotechnologies, Bristol Myers Squibb, Abbvie, Intellia, Epizyme, Alphasights	

**Information accurate at time of printing*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair



C. Ola Landgren, MD, PhD

Professor of Medicine
Chief, Myeloma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

C. Ola Landgren, MD, PhD, earned his MD in 1995 from Karolinska Institute, Stockholm, Sweden. Currently, Dr Landgren is chief of myeloma service at Memorial Sloan Kettering Cancer Center in New York City, New York. Landgren holds a PhD in diagnostics and prognostics in lymphoid malignancies from Karolinska Institute, Stockholm, Sweden. He has published over 300 papers including a definitive prospective cancer screening study showing that myeloma is consistently preceded by a precursor state. Since 2007, Dr Landgren's translational research has particularly focused on the development of early treatment in smoldering myeloma and newly diagnosed multiple myeloma, paired with cell-based and molecular-based minimal residual disease monitoring.

Faculty



Paolo Ghia, MD, PhD

Professor, Medical Oncology
Università Vita Salute San Raffaele
Director, Strategic Research Program on CLL
IRCCS San Raffaele Scientific Institute
Milan, Italy

Paolo Ghia received his MD from the University of Torino, Italy, and received his PhD working at the Basel Institute for Immunology, Switzerland, studying B lymphocyte development. Next, he studied the molecular mechanisms of the pathogenesis of chronic lymphoproliferative disorders, particularly of follicular lymphoma at the Dana-Farber Cancer Institute, Harvard Medical School, Boston.

He is now working in Milano, as Professor of Medical Oncology at the Università Vita-Salute San Raffaele; and Deputy Chairman of the Division of Experimental Oncology, at the affiliated Hospital, where he is Director of the Strategic Research Program on CLL, including a dedicated unit for phase 1 studies.

His research interest is the study of the molecular and cellular mechanisms acting in the natural history of Chronic Lymphocytic Leukemia (CLL), including Monoclonal B-cell Lymphocytosis (MBL). On these topics he has published over 330 manuscripts in peer-reviewed journals.

He is President of the European Research Initiative on CLL (ERIC) and a member of the International Workshop on CLL (iwCLL). He coauthors the EHA-ESMO guidelines for CLL treatment and the ERIC recommendations on IGHV, TP53 and MRD analyses. He is currently Associate Editor for CLL at Hemasphere, the official Journal of the European Hematology Association (EHA).

Faculty

**Aaron C. Logan, MD, PhD**

Associate Professor of Clinical Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, CA

Aaron C. Logan, MD, PhD, is an associate professor of clinical medicine at the University of California, San Francisco (UCSF). His clinical practice focuses on the management of patients with acute leukemias, myelodysplastic syndrome, aplastic anemia and hemophagocytic lymphohistiocytosis. Dr Logan also runs a research laboratory and is director of the Hematologic Malignancies Tissue Bank at UCSF. Dr Logan and his laboratory are interested in methods for evaluating clonotypic diversity in the B and T lymphocyte repertoires in patients, particularly following hematopoietic cell transplantation when used to treat blood cancers, bone marrow failure disorders, and congenital immune deficiencies. Methods used in the laboratory currently include T-cell receptor excision circle and kappa-deleting recombination circle (TREC/KREC) quantification, high-throughput sequencing of immunoglobulin and T-cell receptor genes, and in vitro mixed lymphocyte reactions to identify T cells with specific reactivities. Efforts in the lab are focused on the application of immune repertoire profiling to quantify and track malignancy-, pathogen-, and autoantigen-targeted immune responses following allogeneic transplantation, as well as use of this platform to quantify measurable residual disease in lymphoid malignancies. In Dr Logan's lab, the Hematologic Malignancies Tissue Bank at UCSF has been built into a robust resource for samples isolated from patients with a wide diversity of blood cancers and following transplantation. These samples are made available in a deidentified manner to the UCSF and larger research community for cooperative discovery.

**Reid W. Merryman, MD**

Physician
Dana-Farber Cancer Institute
Instructor in Medicine
Harvard Medical School
Boston, MA


Dr. Merryman received his undergraduate degree from the University of Notre Dame and his medical degree from Harvard Medical School. He completed residency training in internal medicine at Brigham and Women's Hospital and fellowship training in hematology and oncology at Dana-Farber/Partners Cancer Care. He is an attending physician in the Lymphoma Program at Dana-Farber Cancer Institute. His research focuses on the development of immune-based therapies for patients with lymphoma.

Did you miss one of our sessions?


Check out the On-Demand Video Updates
from the Annual Hematology Meeting

—*Rapid Archive from*→ **NEW ORLEANS**


Archives will be available on December 10th




**Optimized use of MRD in
Hematologic Malignancies**




**Maximizing Clinical Practice
for Hodgkin Lymphoma**




State-of-the-Art CMV Care




**State-of-the-Art Care for
MF and PV**




**Emerging Treatments for
Anemia in CKD**




**Exploring Gene Therapy in
Hemophilia B**



**Holistic Approaches in
Sickle Cell Disease Treatment**




**Diagnosing Uncommon
Hematologic Disorders**




**Diagnosis and Treatment of
Hemolytic Anemias**



**Novel Therapies to Prevent
and Treat GvHD**



**Optimized Treatments for
ALL in Adolescents and Adults**



**Novel Treatments for Indolent
and Aggressive B-Cell Lymphomas**



**Multidisciplinary Management
of BPDCN**



**Treating Transfusion-Related
Iron Overload**



Scan the QR code below
or visit gotoper.com/ASH22
to view the symposia archive.

 **PER**[®]
Physicians'
Education
Resource, LLC
gotoper.com